[8-K] Theravance Biopharma, Inc. Reports Material Event

Rhea-AI Filing Summary

Theravance Biopharma (TBPH)

The materials include a press release (Exhibit 99.1) and a slide deck titled Third Quarter 2025 Financial Results and Business Update (Exhibit 99.2). The information in Item 2.02 and Item 9.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed filed under the Exchange Act.

11/10/2025 - 04:11 PM

false 0001583107 0001583107 2025-11-10 2025-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): November 10, 2025

THERAVANCE BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands		001-36033		98-1226628
(State or Other Jurisdiction of		(Commission File Number)		(I.R.S. Employer Identification
Incorporation)				Number)

C/O Theravance Biopharma US, LLC

901 Gateway Boulevard

South San Francisco, CA 94080

(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Share $0.00001 Par Value		TBPH		NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company    ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2025, Theravance Biopharma, Inc. (the “Company”) issued a press release and is holding a conference call regarding its financial results for the quarter ended September 30, 2025, and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and a copy of materials that will accompany the call is furnished as Exhibit 99.2 to this Current Report.

The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

	99.1	Press Release dated November 10, 2025
	99.2	Slide deck entitled Third Quarter 2025 Financial Results and Business Update
	104	Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		THERAVANCE BIOPHARMA, INC.
Date: November 10, 2025		By:	/s/ Aziz Sawaf
			Aziz Sawaf
			Senior Vice President and Chief Financial Officer

FAQ

What did Theravance Biopharma (TBPH) announce in this 8-K?

The company furnished a press release and is holding a conference call for its financial results for the quarter ended September 30, 2025, plus a business update.

Which exhibits are included with TBPH’s 8-K?

Exhibit 99.1 is the press release dated November 10, 2025, and Exhibit 99.2 is a slide deck titled Third Quarter 2025 Financial Results and Business Update.

Is the information in this 8-K considered filed?

No. The information in Item 2.02 and Item 9.01, including Exhibits 99.1 and 99.2, is furnished and not deemed filed under the Exchange Act.

What period do the results cover for TBPH?

The results cover the quarter ended September 30, 2025.

What is Theravance Biopharma’s trading symbol and exchange?

The ordinary shares trade under symbol TBPH on the NASDAQ Global Market.